A Phase 2, Randomized, Efficacy and Safety Study of Imprime PGG Injection in Combination with Cetuximab and Concomitant Paclitaxel and Carboplatin Therapy in Patients with Previously Untreated Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer

Trial Profile

A Phase 2, Randomized, Efficacy and Safety Study of Imprime PGG Injection in Combination with Cetuximab and Concomitant Paclitaxel and Carboplatin Therapy in Patients with Previously Untreated Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs PGG-glucan (Primary) ; Carboplatin; Cetuximab; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Biothera
  • Most Recent Events

    • 24 Mar 2017 Results published in the Biothera Media Release
    • 16 Mar 2017 Results published in the Investigational New Drugs
    • 02 Jun 2015 Results of pooled analysis of two phase II trials presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top